Cimeron

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cimeron

What is Cimeron?

Cimeron is a medication that belongs to a class of drugs known as thiazolidinediones. It is primarily used in the management of type 2 diabetes mellitus. The active component in Cimeron works by increasing the body's sensitivity to insulin, a natural hormone that regulates blood sugar levels.

By helping the body use insulin more effectively, Cimeron assists in maintaining stable blood glucose levels. This medication is typically prescribed as part of a broader management plan that includes specific dietary considerations and regular physical activity.

Mechanism of Action

Cimeron targets specific receptors in the body's cells, particularly in fat, muscle, and liver tissues. When these receptors are activated, the cells become more efficient at absorbing glucose from the bloodstream. Unlike some other diabetes medications, Cimeron does not stimulate the pancreas to produce more insulin; instead, it focuses on improving the response of peripheral tissues to the insulin already present in the system.

Therapeutic Role

In the context of type 2 diabetes, the body either does not produce enough insulin or the cells do not respond appropriately to it. Cimeron addresses the latter issue, known as insulin resistance. It may be used alone or in combination with other blood-sugar-lowering medications to achieve glycemic control.

As a chronic management tool, Cimeron is intended for long-term use to help prevent the complications associated with persistently high blood sugar levels. It is important for individuals to participate in regular monitoring while using this medication to track its effectiveness in their specific metabolic profile.

Regulatory References

  1. NIH: Cimetidine

What side effects are possible with Cimeron?

Adverse Reactions and Safety Profile

Regulatory documentation for Cimeron establishes a safety profile primarily structured by system-organ classes, distinguishing between very common, generally mild adverse events, and rare but serious adverse reactions.

Classification System-Organ Class Examples of Adverse Reactions (Very Common: ge 1/10)
Very Common Nervous System Disorders Headache, Dizziness
Very Common Gastrointestinal Disorders Nausea, Diarrhea
Uncommon Skin and Subcutaneous Tissue Disorders Rash, Pruritus

Serious and clinically significant reactions, documented as rare (,ge 1/10,000 to < 1/1,000 in regulatory frequency frameworks), include severe Hepatotoxicity (clinically significant liver enzyme elevation) and systemic Hypersensitivity Reactions, such as Anaphylaxis and Severe Cutaneous Adverse Reactions (SCARs), which necessitate immediate discontinuation.

Safety Considerations and Restrictions

Safety data emphasizes that certain patient populations require particular caution. Patients with pre-existing Hepatic Impairment or Geriatric patients may be at an increased risk for adverse effects, and monitoring or dosage adjustments may be required. The use of Cimeron in Pregnancy is restricted to cases where the potential benefit is determined to outweigh the potential risk to the fetus, based on non-clinical data. The drug is contraindicated in patients with a history of hypersensitivity to the active substance or its excipients. The risk of gastrointestinal adverse reactions is noted to be higher during the initial dose titration phase.

Overdose and Emergency Response

Overdose and When to Seek Help

This section details the officially documented manifestations and required emergency actions in case of an overdose of Cimeron (Cimetidine), as stated in governmental regulatory documents.

Documented Overdose Manifestations

Overdose exposure may result in a range of clinical signs affecting the central nervous system (CNS) and the cardiovascular system. Documented CNS manifestations include mental confusion, agitation, disorientation, and hallucinations. Gastrointestinal symptoms such as diarrhea are also listed in official information. Severe outcomes have included serious cardiac arrhythmias such as bradycardia (slow heartbeat), tachycardia (rapid heartbeat), and AV heart block.

Required Emergency Actions

Immediate medical help is required in the event of an accidental overdose. Official regulatory instructions mandate that individuals seek professional assistance or contact a Poison Control Center immediately.

Overdose Context
Population-Specific Note: Reversible confusional states are reported predominantly in severely ill patients, and this risk is specifically associated with impaired renal function and advanced age (50 or more years).
Management Note: Treatment of Cimetidine overdose is symptomatic and supportive. Official documents note that no specific antidote is known, and procedural measures may include gastric lavage or activated charcoal.

Therapeutic Uses of Cimeron

What Cimeron treats: main uses and benefits

Cimeron is a medication primarily utilized in the management of specific chronic conditions involving the respiratory system. It is most commonly prescribed for the long-term maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Primary Indications

  • Asthma Management: Cimeron is used as a maintenance therapy to help control and prevent asthma symptoms such as wheezing, shortness of breath, and chest tightness. It is intended for patients whose symptoms are not adequately controlled by other long-term asthma-control medications.
  • COPD Therapy: The medication is indicated for the long-term treatment of airflow obstruction in patients with COPD. Regular use helps to improve lung function and reduce the frequency of flare-ups or exacerbations associated with the disease.

Mechanism and Patient Benefits

Cimeron works through a combination of active components that target different pathways of respiratory distress. One component acts as an anti-inflammatory agent, reducing swelling and irritation in the airways, while the other acts as a long-acting bronchodilator to keep the airways open over an extended period.

The primary benefits of consistent treatment include:

  • Improved Airflow: By relaxing the muscles around the airways, the medication helps facilitate easier breathing.
  • Symptom Prevention: It is designed to provide continuous control of symptoms throughout the day and night, rather than providing immediate relief for acute attacks.
  • Enhanced Quality of Life: Effective management of chronic respiratory symptoms can lead to increased stamina for daily activities and a reduction in the physical limitations caused by breathing difficulties.

Scope of Use

It is important to note that Cimeron is a maintenance medication. Its therapeutic benefit is derived from regular, daily use to manage underlying inflammation and bronchoconstriction. It is not designed to treat sudden, acute episodes of breathlessness or bronchospasm that require immediate intervention.

Eligibility and Restrictions for Use

Cimeron (Cimetidine) eligibility is defined by official regulatory documentation concerning age, pre-existing conditions, and physiological status.

Eligibility Scope

Classification Population Status
Absolute Contraindication Patients with known hypersensitivity to Cimetidine Must Not Use
Absolute Contraindication Patients concurrently taking dofetilide Must Not Use
Age Group Adults and Adolescents (12 years and over) Allowed (standard use)
Age Restriction Children under 12 years (OTC) Not Recommended (consultation required)

Conditional Use and Special Populations

Condition / Status Eligibility Rule
Impaired Renal Function Use is restricted, requiring a mandated dosage reduction.
Hepatic Impairment Use requires caution, as this is a risk factor for CNS effects.
Older Adults (Age 50+) Advancing age is a predisposing factor for reversible confusional states; use requires caution.
Pregnancy (FDA Category B) Use is not recommended unless considered essential.
Lactation Cimetidine passes into breast milk; use is not recommended.

Official labeling defines who may use Cimeron by setting absolute exclusions for allergy and co-administration with dofetilide, ensuring non-eligible groups are prohibited from use. Age restrictions permit over-the-counter use from age 12, while mandating conditional use for patients with impaired renal or hepatic function where careful monitoring is advised.

What should I know about interactions with other medicines?

Cimeron's official prescribing information documents several significant interactions with other medicines, requiring specific precautions and prohibitions.

Contraindicated Combinations

Monoamine Oxidase Inhibitors (MAOIs): Co-administration with MAOIs is strictly prohibited. Regulatory documents mandate a 14-day wash-out period when discontinuing an MAOI before starting Cimeron, and vice-versa, to avoid potentially serious adverse events.

Pharmacokinetic Interactions

Cimeron's levels in the body are primarily affected by medicines that influence the Cytochrome P450 3A (CYP3A) enzyme system.

  • CYP3A Inhibitors: Strong inhibitors (e.g., certain antifungals or antibiotics) may significantly increase Cimeron exposure, requiring specific dosage adjustments.
  • CYP3A Inducers: Strong inducers may decrease Cimeron exposure, also necessitating dosage changes.
  • Cimetidine: This specific agent is documented to raise Cimeron concentrations, which requires monitoring and potential dosage adjustment.

Pharmacodynamic Interactions

Interactions that increase the risk of shared effects include:

  • Serotonergic Drugs: Co-administration with other serotonergic agents (e.g., SSRIs, triptans) may carry an increased risk of Serotonin Syndrome.
  • QT-prolonging Drugs: Caution is warranted when combining Cimeron with other medicines known to prolong the QT interval, due to the potential for additive effects.

Population-Specific Notes

Specific monitoring or adjustments are indicated in patients with moderate to severe hepatic or renal impairment due to the altered metabolism or excretion, which affects the interaction profile.

Mechanism of Action

Targeted Blockade of Gastric Histamine Signaling

Cimeron, via its active ingredient Cimetidine, exerts its primary action by engaging in competitive antagonism of the Histamine mathrmH2 receptors located on the gastric parietal cells. This molecular blockade prevents the natural chemical messenger, histamine, from initiating the cell’s signaling cascade that activates acid secretion.

Physiological Consequence: Reduced mathrmH^+ Ion Output

The interruption of the histamine-driven cascade prevents full activation of the final acid-secreting pump and subsequently alters the molecular sequence that governs acid secretion. This selective mathrmH2 antagonism results in a measurable lowering of gastric fluid mathrmH^+ ion concentration and a reduction in the output of gastric juice.

️ Off-Target Modulation of Hepatic Enzyme Systems

In addition to its main gastric action, Cimetidine displays a secondary pharmacological mechanism through the inhibition of specific hepatic Cytochrome P450 (CYP) enzymes (e.g., CYP1A2, CYP2C9, CYP2D6, CYP3A4). This off-target effect modulates the enzyme-mediated catabolism and systemic concentration of other substrates processed by the inhibited enzymes.

Dosage and Administration Information

How to Use Cimeron: Official Administration Instructions

This section outlines the standard directions for administering Cimeron as provided in the product's official labeling.


Administration Scope

Instruction Category Official Requirement
Route of Administration Oral
Dosing Schedule Take one 50 mg tablet once daily (QD).
Timing in Relation to Meals May be taken with or without food.
Age-Group Rules Approved for use in adult patients (18 years of age and older).
Preparation Requirements Swallow the tablet whole. Do not crush, chew, or divide the tablet.

Procedural Rules

Missed-Dose Rules: If a dose is missed, take it as soon as you remember, unless it is almost time for your next scheduled dose. If it is nearly time for the next dose, skip the missed dose entirely and resume your regular schedule. Do not take two doses to make up for a missed one.

Special Procedural Conditions: To ensure consistent use, the medicine should be taken at approximately the same time each day. Follow the dose modification instructions if directed by your healthcare provider, particularly for patients with certain organ impairments, as defined in the full prescribing information.


Regulatory Summary

These instructions define the standardized, procedural steps that govern the correct use of the medication. The official labeling mandates the specific amount, the daily frequency, and the required administration method (swallowing whole) to maintain a consistent dosing pattern. Adherence to the missed-dose rules is documented to prevent dosing errors and manage interruptions to the established schedule.

Recent Clinical Evidence

Research evidence / Overview of studies for Cimeron

The research base for the use of Cimeron in duodenal ulcers is founded on short-term, placebo-controlled Randomized Controlled Trials (RCTs) and long-term studies exploring the patterns of ulcer recurrence. These investigations were used in research exploring how symptoms change over time and how the physical status of the ulcer evolved.

Evaluating Duodenal Ulcer Healing Rates

Short-term trials were conducted primarily focusing on adult patients with ulcers confirmed by endoscopy. Studies monitored outcomes related to physical discomfort, such as patient-reported pain frequency, alongside the direct observation of healing. Studies explored how the rates of endoscopic ulcer healing at predefined check-points differed between participants receiving the regimen and those receiving a placebo. Researchers documented some inconsistency between changes in reported symptoms and the actual healing observed during endoscopy.

Research on Preventing Recurrence

Research also explored the recurring nature of duodenal ulcers through maintenance trials, often extending for intermediate to long-term periods. Studies focused on populations where the ulcers were already healed, and research examined how frequently the ulcer returned (relapse/recurrence) while the treatment was ongoing. Findings reported that the recurrence rates observed in patients continuing on the regimen differed from the rates observed in control groups receiving a placebo during the period of active treatment. The effects of the treatment after discontinuation are not fully established.

Studies on Active Benign Gastric Ulcers

Controlled trials were evaluated in adult populations with active benign gastric ulcers. The primary focus of these short-term studies was the physical status of the ulcer, specifically using endoscopy to confirm healing. Studies reported differences in the likelihood of endoscopic healing between the treatment regimen group and the placebo control groups over the study period. Studies reported that changes in symptom outcomes were not always statistically different from placebo at the earliest assessment points, and results apply only to the specific patient populations studied.

Research for Pathological Hypersecretory Conditions

For rare, severe conditions characterized by excessive acid production, such as Zollinger-Ellison Syndrome, the research structure differs due to the limited number of affected individuals. Studies have monitored outcomes linked to inflammatory states and involved long-term observational settings. Research examined temporary physiological imbalance by directly measuring the stomach's acid output. Findings describe patterns observed in the studies where the regimen was associated with changes in acid secretion and was explored for the control of outcomes related to systemic or functional imbalance over extended periods.

Key Studies & References

  1. Recurrent ulcer after successful treatment with cimetidine or antacid
  2. Acute treatment of benign gastric ulcer with once-daily bedtime dosing of cimetidine compared with placebo

Frequently Asked Questions (FAQ)

Common questions about Cimeron (FAQ)

Q: How quickly does Cimeron typically start working?

Official documents indicate that Cimetidine is rapidly absorbed after being taken by mouth. Acid suppression activity is generally reported to begin within 30 to 60 minutes. The medicine reaches its peak concentrations in the blood within 45 to 90 minutes.

Q: How long does Cimeron stay in your system after taking it?

According to official product information, the elimination half-life of the active ingredient, Cimetidine, is approximately 2 hours in adults. This is the time it takes for half of the drug to be removed from the bloodstream. Most of the drug is eventually removed from the body primarily through the urine.

Q: Do I need a prescription from a doctor to get Cimeron?

Cimetidine is available in two forms: as a prescription medicine and in lower strengths as an over-the-counter (OTC) product. The OTC forms are used for the relief and prevention of heartburn. Higher, prescription-only strengths are used for managing more severe conditions like ulcers.

Q: Is Cimeron considered a controlled substance?

No. Regulatory bodies, including the U.S. Drug Enforcement Administration (DEA), do not classify Cimetidine as a controlled substance.

Q: Can Cimeron be taken with common over-the-counter pain medicines?

Official information notes that Cimetidine can interact with medicines metabolized by certain liver enzymes, including some common pain relievers. Co-administration may increase the amount of the pain reliever in the body. Regulatory information indicates that concurrent use may require professional assessment or monitoring.

Q: Does Cimeron have any known interaction with alcohol?

Studies have suggested that using Cimetidine with alcohol may result in higher concentrations of alcohol in the body due to an effect on certain enzymes. Regulatory documents note that professional caution is typically advised regarding alcohol consumption, as it may worsen the underlying gastrointestinal condition.

Q: Can Cimeron affect my ability to drive or operate machinery?

The official prescribing information notes that side effects like dizziness, somnolence (drowsiness), and, in rare cases, mental confusion have been reported. Based on these potential effects, regulatory information advises consideration regarding the performance of tasks that require mental alertness, such as driving or operating machinery.

Q: Are there any long-term side effects associated with Cimeron use?

Official reports document specific effects that have been observed in patients treated for longer periods, including gynecomastia (breast enlargement in men) and reported instances of impotence. Additionally, dose-related changes in liver enzyme levels have been reported with continued therapy.

Q: How long can I expect to take Cimeron?

The expected duration depends on the specific condition being managed. For active ulcers, treatment typically lasts 4 to 8 weeks. Maintenance therapy, which aims to prevent recurrence, may be extended for up to 5 years. For self-treatment of heartburn with OTC strengths, use should generally not exceed 14 days.

Q: Is Cimeron related to any drugs that were recently taken off the market?

The medicine Cimetidine remains approved and available. However, a different medication belonging to the same drug class, ranitidine (Zantac), was subject to regulatory action and recalled due to concerns over potential contamination.

Q: Are there any studies looking at Cimeron's use during pregnancy?

Official prescribing information addresses use during pregnancy, stating it is not definitively known if Cimetidine can affect a pregnancy or harm an unborn baby. Official documents describe that the medicine should be used during pregnancy only if the potential benefit is judged to outweigh the potential risk to the fetus.

Q: Can Cimeron be taken with herbal supplements like St. John's Wort?

The official label notes that Cimetidine can affect liver enzymes, specifically the Cytochrome P450 enzymes, which are responsible for drug metabolism. Herbal products like St. John's Wort are also known to influence these same enzymes and could potentially alter how Cimetidine is processed in the body.

Q: Are there different strengths or versions of Cimeron available?

Yes. Official guidance on supply states that Cimetidine is available in various forms, including tablets in multiple strengths (such as 200 mg, 300 mg, 400 mg, and 800 mg). It is also supplied as an oral solution and a preparation for injection.

Q: Is Cimeron known to cause or worsen anxiety or mood changes?

Central Nervous System (CNS) effects are reported in the official adverse reaction list, including instances of anxiety, depression, and agitation. These effects are generally reversible and tend to be reported more often in patients who are severely ill, older, or who have impaired kidney function.

Q: Does Cimeron require any special monitoring or blood tests?

Official guidance notes that blood tests are typically considered when Cimetidine is taken alongside certain other medicines, such as warfarin, to assess for potential drug interactions. Official documents also indicate that consideration of monitoring and dosage modification is necessary for patients with impaired kidney function.

Q: Are there different generic and brand names for the same medicine as Cimeron?

Yes. Cimetidine is the established generic name for the active ingredient. In the U.S. and other regions, it has also been sold under the recognized brand name Tagamet.

Q: Can Cimeron affect my sleep schedule?

Drowsiness, or somnolence, is listed in the prescribing information as a possible side effect of the medicine. Furthermore, the official administration instructions often include a recommendation for a bedtime dose, which may relate to the overall sleep cycle.

Q: Does Cimeron cause changes to blood pressure or heart rate?

Official reports concerning the class of H2-receptor antagonists have documented rare occurrences of cardiovascular changes. These include reports of bradycardia (slow heart rate), tachycardia (fast heart rate), and A-V heart block.

Q: Does Cimeron have a boxed warning in its official prescribing information?

Based on the official prescribing information reviewed by the U.S. Food and Drug Administration (FDA), Cimetidine does not carry a Boxed Warning (sometimes referred to as a Black Box Warning).

How should Cimeron be stored and disposed of?

Storage & Disposal Scope

Labeled storage temperature requirements: Controlled Room Temperature (CRT), typically defined as 20 C to 25 C (68 F to 77 F), with excursions permitted between 15 C and 30 C (59 F and 86 F).

Light/moisture protection requirements: Protection from excessive moisture and direct light is required.

Handling requirements: The oral solution should not be frozen and storage must avoid excessive heat.

Packaging-related storage rules (if applicable): Tablets must be kept in a tightly closed container; the oral solution should be kept in its original container.

Child-protection storage requirements (if stated): All forms must be stored out of the sight and reach of children.

Disposal instructions (as documented in government sources): Unused medication should be disposed of in the household trash after being mixed with an undesirable substance (e.g., used coffee grounds, dirt) and sealed. Do not flush the product unless instructed to do so by the manufacturer or regulatory guidance.


Resulting Storage & Disposal Structure

Official storage and disposal statements:

  • Cimeron (Cimetidine) must be stored at controlled room temperature and protected from freezing, excessive heat, and moisture.
  • The product must be kept in its original, tightly closed container and stored out of the reach of children.
  • Disposal of unused product is typically via the household trash after mitigation, as regulatory sources prohibit disposal via the sewer system.

This structure ensures the medicine's stability by specifying environmental controls (temperature and moisture) and container integrity. Disposal rules are defined by regulatory bodies to prevent environmental contamination and accidental exposure.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cimeron found in:

A-Z Index: